M. Andrew Woodmansee

Drew Woodmansee's practice focuses on patent litigation. He has 20 years of experience representing clients in the pharmaceutical, biotechnology, medical device, and telecommunications industries in federal courts throughout the U.S. He has tried cases to verdict in bench and jury trials, as well as in Section 337 investigations before the U.S. International Trade Commission (ITC).

Prior to joining Jones Day in 2016, Drew represented Scantibodies Laboratory in a patent dispute with Nichols Institute Diagnostics, a subsidiary of Quest Diagnostics. The case involved one bench trial and two jury trials. The jury delivered a defense verdict for Scantibodies, which the U.S. Court of Appeals for the Federal Circuit later affirmed. He also has litigated and tried numerous cases for pharmaceutical clients under the Hatch-Waxman Act. In terms of his most recent experience before the ITC, in 2013 Drew served as lead counsel for Kyocera Corporation in a two-week evidentiary hearing. The Administrative Law Judge concluded that none of the 14 accused Kyocera smartphones infringed any of the asserted patents. [1]